利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

71 条记录 (耗时 0.033 秒)

    ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
    1.
    发明申请
    ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE 有权

    公开(公告)号：US20210008061A1

    公开(公告)日：2021-01-14

    申请号：US17032882

    申请日：2020-09-25

    申请人： Orexo AB

    发明人： Andreas Fischer

    IPC分类号： A61K31/485 ,  A61K9/14 ,  A61K9/20 ,  A61K9/00 ,  A61K31/4748

    摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

    Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
    2.
    发明授权
    Abuse-resistant pharmaceutical composition for the treatment of opioid dependence 有权
    用于治疗阿片样物质依赖性的耐药性药物组合物

    公开(公告)号：US08940330B2

    公开(公告)日：2015-01-27

    申请号：US14127470

    申请日：2012-09-18

    申请人： Orexo AB

    发明人： Andreas Fischer

    IPC分类号： A61K9/20 ,  A61K31/485 ,  A61K9/14 ,  A61K9/00

    CPC分类号： A61K31/485 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2095 ,  A61K31/4748

    摘要： There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

    摘要翻译： 提供了用于治疗例如药物的药物组合物。 包含药理学有效量的丁丙诺啡或其药学上可接受的盐的微粒与包含弱酸的微粒或包含弱酸性缓冲液形成材料的颗粒的缔合混合物中的阿片样物质依赖性。 组合物还可以包含崩解剂和/或药理学有效量的纳洛酮或其药学上可接受的盐的颗粒。 该组合物可用于治疗阿片依赖性/成瘾和/或疼痛。

    NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS
    5.
    发明申请
    NON-ABUSABLE PHARMACEUTICAL COMPOSITION COMPRISING OPIOIDS 有权
    不可逆药用组合物包含OPIOIDS

    公开(公告)号：US20130195981A1

    公开(公告)日：2013-08-01

    申请号：US13799117

    申请日：2013-03-13

    申请人： Orexo AB

    发明人： Anders Pettersson

    IPC分类号： A61K9/16 ,  A61K31/4468 ,  A61K31/485

    CPC分类号： A61K31/485 ,  A61K9/006 ,  A61K9/14 ,  A61K9/167 ,  A61K9/1676 ,  A61K9/2077 ,  A61K9/5084 ,  A61K31/4468

    摘要： There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.

    摘要翻译： 提供了用于治疗疼痛的药物组合物，其包含药理学有效量的阿片类镇痛药或其药学上可接受的盐，其以颗粒形式存在于包含药理学有效量的阿片样物质拮抗剂的载体颗粒的表面上， 或其药学上可接受的盐，其载体颗粒的尺寸大于阿片样物质镇痛剂的颗粒。 这些成分也可用于预防吸毒者滥用阿片样物质。

    Gastric acid secretion inhibiting composition
    8.
    发明申请
    Gastric acid secretion inhibiting composition 审中-公开
    胃酸分泌抑制组合物

    公开(公告)号：US20110104264A1

    公开(公告)日：2011-05-05

    申请号：US12803982

    申请日：2010-07-12

    申请人： Anders Pettersson

    发明人： Anders Pettersson

    IPC分类号： A61K9/48 ,  A61K9/20 ,  A61K9/14 ,  A61K31/435 ,  A61K31/4164 ,  A61K31/426 ,  A61P1/04

    CPC分类号： A61K9/5084 ,  A61K9/0095 ,  A61K9/167 ,  A61K9/2081 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/5078 ,  A61K31/341 ,  A61K31/4164 ,  A61K31/426 ,  A61K31/4439 ,  A61K2300/00

    摘要： A method for the treatment of at least one symptom of gastro-esophageal reflux disease (GERD) in a human suffering from GERD administers an oral pharmaceutical dosage form into a gastro-intestinal tract of a human suffering from GERD. The oral pharmaceutical dosage form contains an acid susceptible proton pump inhibitor or salt thereof (PPI), an H2 receptor antagonist or salt thereof (H2RA), a pharmaceutically acceptable carrier, and optionally an antacid agent and/or alginate. The PPI is selected from lansoprazole, omeprazole, pantoprazole, rabeprazole, pariprazole, leminoprazole, their pharmaceutically acceptable salts, enantiomers and salts of enantiomers and is in a form that protects the PPI from degradation in a stomach. The H2RA is selected from cimetidine, ranitidine, nizatidine and famotidine, their pharmaceutically acceptable salts, isomers and salts of isomers. The PPI is administered in combination with the H2RA for passage into a small

    摘要翻译： 在患有GERD的人中治疗胃食管反流病（GERD）的至少一种症状的方法将口服药物剂型给予患有GERD的人的胃肠道。 口服药物剂型含有酸敏感质子泵抑制剂或其盐（PPI），H 2受体拮抗剂或其盐（H2RA），药学上可接受的载体和任选的抗酸剂和/或藻酸盐。 PPI选自兰索拉唑，奥美拉唑，泮托拉唑，雷贝拉唑，替比拉唑，雷米拉唑，其药学上可接受的盐，对映异构体和对映体盐，并且是保护PPI免于胃中降解的形式。 H2RA选自西咪替丁，雷尼替丁，尼札替丁和法莫替丁，其药学上可接受的盐，异构体和异构体盐。 PPI与H2RA联合施用以通入小型

    Method and means for detecting inflammatory processes
    9.
    发明授权
    Method and means for detecting inflammatory processes 失效
    检测炎症过程的方法和手段

    公开(公告)号：US06962687B1

    公开(公告)日：2005-11-08

    申请号：US10110040

    申请日：2000-10-24

    申请人： Anders Pettersson ,  Thomas Lundqvist

    发明人： Anders Pettersson ,  Thomas Lundqvist

    IPC分类号： A61B5/08 ,  A61K49/00 ,  A61K51/02 ,  A61K51/12 ,  G01N33/487 ,  G01N33/493 ,  G01N33/497 ,  G01N33/50 ,  A61K51/00 ,  A61M36/14

    CPC分类号： A61B5/412 ,  A61B5/0813 ,  A61K51/02 ,  A61K51/1206

    摘要： A method of detecting inflammatory processes comprises (a) administering per-orally or per-rectally a composition comprising a diagnostically effective amount of L-[guanido-15N2]-arginine, L-[guanido-15N]-arginine, their mixtures and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier; (b) collecting a sample of exhaled air, saliva or urine; (c) determining 13NO in the air sample or its transformation products 15IN-nitrite and/or 15N-nitrate in the saliva sample or urine. Also disclosed is a corresponding diagnostic composition for use in diagnosing inflammatory processes and a method for its manufacture.

    摘要翻译： 一种检测炎症过程的方法包括（a）每口服或每次直肠给予包含诊断有效量的L- [胍基-N 15 N 2 - 精氨酸，L- [胍基-N 15 N] - 精氨酸，它们的混合物和药学上可接受的盐，以及药学上可接受的载体; （b）收集呼出的空气，唾液或尿样品; （c）在唾液样品中测定空气样品或其转化产物中的亚硝酸盐和/或15％硝酸盐中的<13+ 或尿液。 还公开了用于诊断炎性过程的相应诊断组合物及其制造方法。

    Pharmaceutical composition for nasal delivery
    10.
    发明授权
    Pharmaceutical composition for nasal delivery 有权

    公开(公告)号：US11883392B2

    公开(公告)日：2024-01-30

    申请号：US17172635

    申请日：2021-02-10

    申请人： Orexo AB

    发明人： Jonas Sävmarker ,  Robert Rönn ,  Andreas Fischer

    IPC分类号： A61K9/00 ,  A61K9/14 ,  A61K9/16 ,  A61K31/485

    CPC分类号： A61K31/485 ,  A61K9/0043 ,  A61K9/1652 ,  A61K9/1682

    摘要： According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.